THROMBOSIS AND HAEMOSTASIS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ，拒的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0 偏重的研究方向：血液 经验分享：我投稿8天了，依然处于Awaiting Admin Processing，稿号TH-22-04-0201 不知道是否正常，你们都啥情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0 偏重的研究方向：心血管医学 经验分享：5月24号投稿，到现在Awaiting EIC Decision已经快10天了，是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：静脉血栓;孟德尔随机化 经验分享：Submit:30-Jul-2023 Major Revision:27-Aug-2023 Minor Revision:18-Oct-2023 Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修，小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月，共两个Review，审稿人意见比较苛刻，重视体内数据和临床意义，是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=348, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544262, encodeId=8501544262e6, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836976, encodeId=2ab68369e602, content=已投，23天给意见major revision,修回后目前awaiting reviewer scores中。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Thu Jun 15 00:31:04 CST 2017, time=2017-06-15, status=1, ipAttribution=)]

2023-12-23 2606467171 来自四川省

awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ，拒的可能性大吗？

15 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ，拒的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0 偏重的研究方向：血液 经验分享：我投稿8天了，依然处于Awaiting Admin Processing，稿号TH-22-04-0201 不知道是否正常，你们都啥情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0 偏重的研究方向：心血管医学 经验分享：5月24号投稿，到现在Awaiting EIC Decision已经快10天了，是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：静脉血栓;孟德尔随机化 经验分享：Submit:30-Jul-2023 Major Revision:27-Aug-2023 Minor Revision:18-Oct-2023 Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修，小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月，共两个Review，审稿人意见比较苛刻，重视体内数据和临床意义，是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=348, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544262, encodeId=8501544262e6, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836976, encodeId=2ab68369e602, content=已投，23天给意见major revision,修回后目前awaiting reviewer scores中。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Thu Jun 15 00:31:04 CST 2017, time=2017-06-15, status=1, ipAttribution=)]

2022-05-03 120e7c52m79(暂无昵称)

投稿命中率:25.0
偏重的研究方向：血液
经验分享：我投稿8天了，依然处于Awaiting Admin Processing，稿号TH-22-04-0201
不知道是否正常，你们都啥情况？

48 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ，拒的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0 偏重的研究方向：血液 经验分享：我投稿8天了，依然处于Awaiting Admin Processing，稿号TH-22-04-0201 不知道是否正常，你们都啥情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0 偏重的研究方向：心血管医学 经验分享：5月24号投稿，到现在Awaiting EIC Decision已经快10天了，是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：静脉血栓;孟德尔随机化 经验分享：Submit:30-Jul-2023 Major Revision:27-Aug-2023 Minor Revision:18-Oct-2023 Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修，小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月，共两个Review，审稿人意见比较苛刻，重视体内数据和临床意义，是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=348, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544262, encodeId=8501544262e6, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836976, encodeId=2ab68369e602, content=已投，23天给意见major revision,修回后目前awaiting reviewer scores中。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Thu Jun 15 00:31:04 CST 2017, time=2017-06-15, status=1, ipAttribution=)]

2022-06-07 ms8000000183735007

投稿命中率:50.0
偏重的研究方向：心血管医学
经验分享：5月24号投稿，到现在Awaiting EIC Decision已经快10天了，是不是没戏了。

29 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ，拒的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0 偏重的研究方向：血液 经验分享：我投稿8天了，依然处于Awaiting Admin Processing，稿号TH-22-04-0201 不知道是否正常，你们都啥情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0 偏重的研究方向：心血管医学 经验分享：5月24号投稿，到现在Awaiting EIC Decision已经快10天了，是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：静脉血栓;孟德尔随机化 经验分享：Submit:30-Jul-2023 Major Revision:27-Aug-2023 Minor Revision:18-Oct-2023 Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修，小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月，共两个Review，审稿人意见比较苛刻，重视体内数据和临床意义，是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=348, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544262, encodeId=8501544262e6, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836976, encodeId=2ab68369e602, content=已投，23天给意见major revision,修回后目前awaiting reviewer scores中。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Thu Jun 15 00:31:04 CST 2017, time=2017-06-15, status=1, ipAttribution=)]

2023-11-02 一步之遥、来自浙江省

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：静脉血栓;孟德尔随机化
经验分享：Submit:30-Jul-2023
Major Revision:27-Aug-2023
Minor Revision:18-Oct-2023
Accept:26-Oct-2023

22 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ，拒的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0 偏重的研究方向：血液 经验分享：我投稿8天了，依然处于Awaiting Admin Processing，稿号TH-22-04-0201 不知道是否正常，你们都啥情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0 偏重的研究方向：心血管医学 经验分享：5月24号投稿，到现在Awaiting EIC Decision已经快10天了，是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：静脉血栓;孟德尔随机化 经验分享：Submit:30-Jul-2023 Major Revision:27-Aug-2023 Minor Revision:18-Oct-2023 Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修，小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月，共两个Review，审稿人意见比较苛刻，重视体内数据和临床意义，是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=348, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544262, encodeId=8501544262e6, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836976, encodeId=2ab68369e602, content=已投，23天给意见major revision,修回后目前awaiting reviewer scores中。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Thu Jun 15 00:31:04 CST 2017, time=2017-06-15, status=1, ipAttribution=)]

2021-12-28 MS68862005

模型图对审稿人对稿件的态度是有利还是不利？

36 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ，拒的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0 偏重的研究方向：血液 经验分享：我投稿8天了，依然处于Awaiting Admin Processing，稿号TH-22-04-0201 不知道是否正常，你们都啥情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0 偏重的研究方向：心血管医学 经验分享：5月24号投稿，到现在Awaiting EIC Decision已经快10天了，是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：静脉血栓;孟德尔随机化 经验分享：Submit:30-Jul-2023 Major Revision:27-Aug-2023 Minor Revision:18-Oct-2023 Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修，小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月，共两个Review，审稿人意见比较苛刻，重视体内数据和临床意义，是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=348, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544262, encodeId=8501544262e6, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836976, encodeId=2ab68369e602, content=已投，23天给意见major revision,修回后目前awaiting reviewer scores中。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Thu Jun 15 00:31:04 CST 2017, time=2017-06-15, status=1, ipAttribution=)]

2021-12-27 ms6000000264964247

实验数据被抢先发表了怎么办？

34 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ，拒的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0 偏重的研究方向：血液 经验分享：我投稿8天了，依然处于Awaiting Admin Processing，稿号TH-22-04-0201 不知道是否正常，你们都啥情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0 偏重的研究方向：心血管医学 经验分享：5月24号投稿，到现在Awaiting EIC Decision已经快10天了，是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：静脉血栓;孟德尔随机化 经验分享：Submit:30-Jul-2023 Major Revision:27-Aug-2023 Minor Revision:18-Oct-2023 Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修，小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月，共两个Review，审稿人意见比较苛刻，重视体内数据和临床意义，是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=348, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544262, encodeId=8501544262e6, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836976, encodeId=2ab68369e602, content=已投，23天给意见major revision,修回后目前awaiting reviewer scores中。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Thu Jun 15 00:31:04 CST 2017, time=2017-06-15, status=1, ipAttribution=)]

2017-12-15 ms4391593229390302

2次大修后再一次小修，小修返回后第二天被接收了

174 0

[GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ，拒的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0 偏重的研究方向：血液 经验分享：我投稿8天了，依然处于Awaiting Admin Processing，稿号TH-22-04-0201 不知道是否正常，你们都啥情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0 偏重的研究方向：心血管医学 经验分享：5月24号投稿，到现在Awaiting EIC Decision已经快10天了，是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：静脉血栓;孟德尔随机化 经验分享：Submit:30-Jul-2023 Major Revision:27-Aug-2023 Minor Revision:18-Oct-2023 Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修，小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月，共两个Review，审稿人意见比较苛刻，重视体内数据和临床意义，是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=348, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544262, encodeId=8501544262e6, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836976, encodeId=2ab68369e602, content=已投，23天给意见major revision,修回后目前awaiting reviewer scores中。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Thu Jun 15 00:31:04 CST 2017, time=2017-06-15, status=1, ipAttribution=)]

2017-11-05 peterread

审稿速度:1.0 | 投稿命中率:25.0
经验分享：一审一个月，共两个Review，审稿人意见比较苛刻，重视体内数据和临床意义，是ESC血栓和动脉粥样硬化工作组的官方杂志

348 0

[GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ，拒的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0 偏重的研究方向：血液 经验分享：我投稿8天了，依然处于Awaiting Admin Processing，稿号TH-22-04-0201 不知道是否正常，你们都啥情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0 偏重的研究方向：心血管医学 经验分享：5月24号投稿，到现在Awaiting EIC Decision已经快10天了，是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：静脉血栓;孟德尔随机化 经验分享：Submit:30-Jul-2023 Major Revision:27-Aug-2023 Minor Revision:18-Oct-2023 Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修，小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月，共两个Review，审稿人意见比较苛刻，重视体内数据和临床意义，是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=348, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544262, encodeId=8501544262e6, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836976, encodeId=2ab68369e602, content=已投，23天给意见major revision,修回后目前awaiting reviewer scores中。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Thu Jun 15 00:31:04 CST 2017, time=2017-06-15, status=1, ipAttribution=)]

2017-07-16 zheyang

还是5分多,虽然没有大变化,能稳定在些,也算是中上等

251 0

[GetPortalCommentsPageByObjectIdResponse(id=2176663, encodeId=f7c121e666302, content=awaiting reviewer scores 后11天后变成了Awaiting SE Recommendation ，拒的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Sat Dec 23 10:23:14 CST 2023, time=2023-12-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1216555, encodeId=ba5d121655554, content=投稿命中率:25.0 偏重的研究方向：血液 经验分享：我投稿8天了，依然处于Awaiting Admin Processing，稿号TH-22-04-0201 不知道是否正常，你们都啥情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b2e2216153, createdName=120e7c52m79(暂无昵称), createdTime=Tue May 03 14:04:00 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224943, encodeId=bede122494364, content=投稿命中率:50.0 偏重的研究方向：心血管医学 经验分享：5月24号投稿，到现在Awaiting EIC Decision已经快10天了，是不是没戏了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc5b5422035, createdName=ms8000000183735007, createdTime=Tue Jun 07 12:45:03 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166341, encodeId=fbc72166341ba, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：静脉血栓;孟德尔随机化 经验分享：Submit:30-Jul-2023 Major Revision:27-Aug-2023 Minor Revision:18-Oct-2023 Accept:26-Oct-2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220102/e596621ff7ca4602b0af813517c72811/c6ec383c45484fd78c6ed80849d0e129.jpg, createdBy=81935632595, createdName=一步之遥、, createdTime=Thu Nov 02 18:29:17 CST 2023, time=2023-11-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1098101, encodeId=ebeb109810186, content=模型图对审稿人对稿件的态度是有利还是不利？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098102, encodeId=0f67109810229, content=实验数据被抢先发表了怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=839911, encodeId=0f558399117c, content=2次大修后再一次小修，小修返回后第二天被接收了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dee5413979, createdName=ms4391593229390302, createdTime=Fri Dec 15 19:21:28 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548925, encodeId=fa0554892581, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月，共两个Review，审稿人意见比较苛刻，重视体内数据和临床意义，是ESC血栓和动脉粥样硬化工作组的官方杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=348, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da2b2190065, createdName=peterread, createdTime=Sun Nov 05 18:26:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544262, encodeId=8501544262e6, content=还是5分多,虽然没有大变化,能稳定在些,也算是中上等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zheyang, createdTime=Sun Jul 16 19:03:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=836976, encodeId=2ab68369e602, content=已投，23天给意见major revision,修回后目前awaiting reviewer scores中。。。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ed45414080, createdName=ms9537892490195010, createdTime=Thu Jun 15 00:31:04 CST 2017, time=2017-06-15, status=1, ipAttribution=)]

2017-06-15 ms9537892490195010

已投，23天给意见major revision,修回后目前awaiting reviewer scores中。。。

140 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务